Trisalus Life Sciences Inc. has announced the publication of clinical data from a single-center study evaluating its Pressure-Enabled Drug Delivery (PEDD) technology for thyroid parenchymal embolization. This study, published in the Journal of the Endocrine Society, assesses the safety, feasibility, and early efficacy of Pressure-Enabled Thyroid Artery Embolization (PED-TAE) using the TriNav® Infusion System. The study involved 22 patients with symptomatic thyroid disease, resulting in 100% technical and clinical success and a 73% mean reduction in thyroid gland volume at six months without major complications. These findings mark an expansion of the company's technology applications beyond liver cancers, offering insights into new treatment options for thyroid disease.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.